Education
About Us
Working with TipRanks
Follow Us
Applied DNA Sciences (APDN)
NASDAQ:APDN
Top Page
Applied DNA Sciences
(NASDAQ:APDN)
42Neutral
Applied DNA Sciences (APDN) vs. S&P 500 (SPY)
Market Cap
$5.85M
Dividend YieldN/A
Average Volume (3M)2.42M
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue Growth-58.46%
EPS Growth47.98%
CountryUS
Employees46
SectorHealthcare
Sector Strength64
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-285.87
Shares Outstanding6,497,790
10 Day Avg. Volume1,326,598
30 Day Avg. Volume2,421,173
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.53
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Applied DNA Sciences Business Overview & Revenue Model
Company DescriptionApplied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
How the Company Makes MoneyApplied DNA Sciences generates revenue through the sale of its proprietary DNA-based solutions and services. The company earns money by providing DNA tagging and authentication services to businesses in various industries, including pharmaceuticals, textiles, and consumer goods. Additionally, APDN collaborates with partners in sectors like government and law enforcement to deliver security solutions. Key revenue streams include service fees for DNA tagging and authentication, as well as licensing fees from strategic partnerships. APDN's earnings are significantly influenced by its ability to secure contracts with major companies and government agencies, as well as its continued innovation in DNA technology applications.
Applied DNA Sciences Financial Statement Overview
Summary
Applied DNA Sciences is facing significant financial challenges with declining revenues and consistent net losses impacting profitability. The balance sheet is stable with low debt, but negative cash flows indicate operational inefficiencies. The company should focus on revenue growth and cost management to improve financial health.Income Statement
The company shows a declining revenue trend with significant losses. Revenue has decreased from $18.17 million in 2022 to $3.73 million TTM. Gross profit margin is low, and net profit margin is negative due to substantial net losses. These indicators suggest weak profitability and potential financial challenges.40
Negative
Balance Sheet
The balance sheet reveals a low debt-to-equity ratio, indicating minimal leverage and a stronger equity position. However, the equity ratio shows a decline from 58% in 2022 to 80% TTM, reflecting reduced asset base and increased equity. The return on equity is negative, which highlights profitability issues.50
Neutral
Cash Flow
Cash flows are under pressure with negative operating cash flow and free cash flow, indicating cash burn. Although financing cash flow is positive due to external funding, reliance on financing for operations is risky. Free cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation.35
Negative
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.74M | 3.43M | 13.37M | 18.17M | 9.03M | 1.93M | Gross Profit |
| 1.28M | 1.02M | 5.53M | 5.05M | 4.93M | 1.21M | EBIT |
| -13.20M | -14.02M | -10.95M | -13.97M | -12.29M | -12.53M | EBITDA |
| -12.80M | -14.02M | -9.59M | -12.68M | -11.68M | -12.25M | Net Income Common Stockholders |
| -8.53M | -6.99M | -9.95M | -8.38M | -16.03M | -12.76M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 468.33K | 6.43M | 7.15M | 15.22M | 6.55M | 7.79M | Total Assets |
| 1.77M | 12.79M | 13.65M | 22.27M | 14.42M | 11.34M | Total Debt |
| 2.63M | 739.16K | 1.24M | 0.00 | 0.00 | 2.35M | Net Debt |
| 2.16M | -5.69M | -5.91M | -15.22M | -6.55M | -5.44M | Total Liabilities |
| 3.58M | 3.82M | 8.78M | 9.36M | 3.30M | 5.63M | Stockholders Equity |
| -1.80M | 9.14M | 4.95M | 12.91M | 11.11M | 5.72M |
| Cash Flow | Free Cash Flow | ||||
| -13.80M | -14.12M | -6.30M | -9.47M | -15.94M | -12.21M | Operating Cash Flow |
| -13.28M | -13.71M | -6.22M | -8.98M | -13.39M | -11.14M | Investing Cash Flow |
| -524.78K | -407.90K | -1.10M | -489.55K | -2.55M | -1.06M | Financing Cash Flow |
| 19.74M | 13.40M | 0.00 | 18.13M | 14.70M | 19.43M |
Applied DNA Sciences Technical Analysis
Negative
0.86
Price Trends
3.82
Negative
6.62
Negative
20.38
Negative
Market Momentum
-0.78
Negative
22.18
Positive
25.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APDN, the sentiment is Negative. The current price of 0.86 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 3.82, and below the 200-day MA of 20.38, indicating a bearish trend. The MACD of -0.78 indicates Negative momentum. The RSI at 22.18 is Positive, neither overbought nor oversold. The STOCH value of 25.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APDN.
Applied DNA Sciences Risk Analysis
Applied DNA Sciences disclosed 41 risk factors in its most recent earnings report. Applied DNA Sciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Applied DNA Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $8.45M | ― | -279.80% | ― | 23.21% | 57.43% | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
48 Neutral | $8.20M | ― | -32.35% | ― | 21.95% | 39.43% | |
42 Neutral | $5.85M | ― | -100.40% | ― | -58.46% | 47.98% | |
39 Underperform | $3.00M | ― | -191.51% | ― | -6.42% | 24.85% | |
29 Underperform | $1.73M | ― | -280.02% | ― | ― | 71.89% |
* Healthcare Sector Average
Performance Comparison
APDN
Applied DNA Sciences
0.86
-249.14
-99.66%
PRPO
Precipio
7.70
1.52
24.60%
NDRA
ENDRA Life Sciences
3.45
-420.93
-99.19%
INBS
Intelligent Bio Solutions
1.30
-1.17
-47.37%
ISPC
iSpecimen
1.17
-4.43
-79.11%
BGLC
BioNexus Gene Lab Corp
2.89
-3.03
-51.18%
Applied DNA Sciences Earnings Call Summary
Earnings Call Date: Feb 13, 2025 | % Change Since: -90.13% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While there were notable achievements in revenue growth, operational improvements, and strategic refocus on LineaRx, the exit from a business segment, workforce reduction, and ongoing financial challenges cast a shadow on the overall performance.Highlights
Increased Revenue
Total revenues for the first quarter of fiscal 2025 were $1.2 million, compared with $891,000 for the same period of fiscal 2024. This increase was driven by higher product revenue from DNA tagging and increased isotopic testing services.
Reduction in Operating Loss
Operating loss for the first quarter was $3 million, compared with $3.8 million in the prior year period, due to lower selling, general, and administrative costs.
GMP Site Certification
Certification of the GMP Site One facility has been completed, allowing for the production of DNA at scale.
Strategic Focus on LineaRx
The company has restructured to focus on the LineaRx subsidiary, aiming to capitalize on the growing demand for enzymatically produced DNA.
LineaRx Customer Growth
In fiscal 2024, LineaRx engaged over 25 customer projects, with expectations for multiple projects to enter the clinic in 2025.
Launch of New Product - Linea Donor DNA
Linea Donor DNA is a high-fidelity DNA form optimized for CRISPR gene editing, available for research use, with GMP availability targeted for later in the year.
Lowlights
Exit and Workforce Reduction in DNA Tagging
The company is exiting the DNA tagging and security products segment, leading to a workforce reduction of approximately 20% and a one-time charge of $300,000.
Substantial Doubt as a Going Concern
The company's 10-Q filing maintains a disclosure of substantial doubt of a going concern, highlighting the need to raise capital and generate revenues.
Net Loss Increase
Net loss for the first quarter was $2.7 million, compared with $1.1 million in the prior year period, despite improvements in operating loss.
Company Guidance
During the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results call, significant guidance was provided regarding the company's strategic restructuring and financial performance. The company reported total revenues of $1.2 million for the first quarter, a notable increase from $891,000 in the same period of fiscal 2024. This growth stemmed from higher product revenue in the DNA tagging business and increased isotopic testing services revenue. However, the operating loss improved to $3 million from $3.8 million in the previous year, attributed to reduced selling, general, and administrative costs. A net loss of $2.7 million was recorded, compared to a $1.1 million loss in the prior year, due to an unrealized gain on the change in the fair value of warrants. The cash and cash equivalents as of December 31st stood at $9.3 million. The company also highlighted a strategic pivot to focus on its LineaRx subsidiary, exiting the DNA tagging segment and reducing the workforce by approximately 20%. This restructuring aims to optimize the cost structure and capitalize on the growing demand for synthetic DNA manufacturing, setting the stage for improved shareholder value and future growth opportunities.Applied DNA Sciences Corporate Events
Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Applied DNA Sciences Approves Reverse Stock Split
Neutral
Mar 12, 2025
On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.